We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Coronary Artery Calcium Scans May Help Lower Heart Disease Risk

By HospiMedica International staff writers
Posted on 05 Apr 2011
A new study of coronary artery-calcium scanning, a simple, noninvasive test that gives patients baseline data about plaque in their coronary arteries, has revealed that the scan helps them make healthy lifestyle changes and lower their heart disease risk factors.

The study, the EISNER trial (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research), was headed by researchers at Cedars-Sinai Heart Institute (Los Angeles, CA, USA) and Cedars-Sinai's S. More...
Mark Taper Foundation imaging department, and was published in the April 12, 2011, issue of the Journal of the American College of Cardiology.

The large clinical trial of volunteers with coronary risk factors but no known heart disease randomized patients to either have or not have a coronary calcium scan and then followed the patients for their risk-factor changes over four years. The final trial result demonstrated that early screening does not increase subsequent tests and their associated costs.

"In our study, patients who knew their coronary calcium scores improved their coronary heart disease risk compared with those with no scan, and those with high calcium scores were motivated to take even more aggressive steps to reduce their risk,” said Daniel S. Berman, MD, the study's lead investigator and chief of Cardiac Imaging and Nuclear Cardiology at the Cedars-Sinai Heart Institute and Cedars-Sinai's S. Mark Taper Foundation Imaging Department.

Coronary artery calcium scanning reveals plaques in coronary arteries long before symptoms develop, and has been consistently shown to identify effectively patients with silent heart disease and those at risk for a heart attack or sudden death. The scanning is seldom covered by insurance in the United States although numerous, consistent studies demonstrate that it identifies these patients more accurately than conventional blood tests. Scanning was performed using electron beam imaging, developed by GE Healthcare-Imatron (Chalfont St. Giles, UK) or multislice computed tomography (CT), developed by Siemens Healthcare (Erlangen, Germany).

The current study's findings found that patients who were screened had better long-term risk profiles than those who were not. All 2,137 study volunteers in the EISNER trial had an initial, private risk factor counseling session and evaluation of seven modifiable risk factors: blood pressure, cholesterol and triglyceride profiles, blood sugar, weight, waist circumference, exercise, and smoking.

Of the total participants, 1,424 were selected at random to have a coronary artery calcium scan. The remaining 713 were assigned to a no-scan group. Four years later, all available participants were reevaluated in the clinic and both groups had coronary artery calcium scans.

Compared to the no-scan group, patients who underwent initial scanning had significant improvement in several risk factors after four years: systolic blood pressure; low-density lipoprotein (LDL) levels; waist size among those with large abdominal circumference; and weight among those who were overweight.

A significant outcome was that the Framingham Risk Score, the broadly used assessment tool that calculates an individual's overall risk of having a heart attack or dying within 10 years, increased in the no-scan group, but remained unchanged in those who had initial scans. Individual risk factor profiles, based on the seven modifiable risk factors, improved in both groups, but the degree of improvement was greater in the scan group.

There was no difference between the groups in the costs or use of invasive or noninvasive diagnostic and treatment procedures. Patients who had normal baseline scans had fewer tests and procedures in the subsequent four years, compared to patients who did not have scans. Drug costs were 7% higher in the scan group because more of these patients started taking blood pressure and cholesterol medications.

Dr. Berman concluded, "A large number of studies has consistently shown that coronary calcium scanning adds to standard risk factor assessment in predicting heart attacks and cardiac death. By showing improved patient outcomes with scanning without increasing the need for subsequent tests--the EISNER study will be very helpful in our quest to prevent heart attacks. The test isn't for everyone, but should be considered in patients with risk factors for coronary artery disease who are in the right age group.”

Related Links:
Cedars-Sinai Heart Institute
GE Healthcare
Siemens Healthcare


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.